Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO GI 2024 | Pembrolizumab, bevacizumab & CAPOX for pMMR/MSS mCRC in the POCHI trial

Shouki Bazarbashi, MBBS, Alfaisal University & King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, gives an overview of results from the Phase II POCHI trial (NCT04262687), which examined pembrolizumab with CAPOX and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate. The investigational therapy showed promising response rates, and recruitment is ongoing. The findings suggest that this subset of patients with pMMR/MSS mCRC may benefit from immunotherapy. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.